Trefoil factor 1 (pS2/TFF1), a peptide with numerous functions;Le facteur en trèfle 1 (pS2/TFF1), un peptide aux multiples facettes

Bulletin du Cancer

Volumn 92, Issue 9, 2005, Pages 773-781

  Mathelin, Carole ^a,b,c   Tomasetto, Catherine ^c   Rio, Marie Christine ^c  

^a CENTRE PAUL STRAUSS   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Cancer; Gut diseases; pS2; TFF1; Trefoil factor; Tumor suppressor gene

Indexed keywords

ANTIESTROGEN; MUCIN; TREFOIL PEPTIDE; TREFOIL PEPTIDE 1; TREFOIL PEPTIDE 2; TREFOIL PEPTIDE 3; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER; CANCER HORMONE THERAPY; ENTEROPATHY; EPITHELIUM CELL; GENE OVEREXPRESSION; HUMAN; INFLAMMATORY DISEASE; MUCOSAL IMMUNITY; PROGNOSIS; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; STOMACH TUMOR; TISSUE REGENERATION; TUMOR SUPPRESSOR GENE; ULCER; WOUND HEALING;

ADENOMA; ANIMALS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; GASTRIC MUCOSA; GASTROINTESTINAL TRACT; GENES, TUMOR SUPPRESSOR; HUMANS; INTESTINE, LARGE; MEMBRANE PROTEINS; MICE; NEOPLASM INVASIVENESS; NEOPLASMS; ORGAN SPECIFICITY; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SUBSTRATE SPECIFICITY; TUMOR SUPPRESSOR PROTEINS;

EID: 26844484642     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 1982; 10: 7895-903.
2. Thim L, Thomsen J, Christensen M, Jorgensen KH. The amino acid sequence of pancreatic spasmolytic polypeptide. Biochim Biophys Acta 1985; 827: 410-8.
3. Suemori S, Lynch-Devaney K, Podolsky DK. Identification and characterization of rat intestinal trefoil factor: tissue- and cell-specific member of the trefoil protein Family. Proc Natl Acad Sci USA 1991; 88: 11017-21.
4. Srivatsa G, Giraud AS, Ulaganathan M, Yeomans ND, Dow C, Nicoll AJ. Biliary epithelial trefoil peptide expression is increased in biliary diseases. Histopathalogy 2002; 40: 261-8.
5. Devine DA, High AS, Owen PJ, Poulsom R, Bonass WA. Trefoil factor expression in normal and diseased human salivary glands. Hum Pathol 2000; 31: 509-15.
6. Dos Santos Silva E, Ulrich M, Doring G, Botzenhart K, Gott P. Trefoil factor family domain peptides in the human respiratory tract. J Pathol 2000; 190: 133-42.
7. Lee SH, Lee SH, Oh BH, Lee HM, Choi JO, Jung KY. Expression of mRNA of trefoil factor peptides in human nasal mucosa. Acta Otolaryngol 2001; 121: 849-53.
8. Wiede A, Hinz M, Canzler E, Franke K, Quednow C, Hoffmann W. Synthesis and localization of the mucin-associated TFF-peptides in the human uterus. Cell Tissue Res 2001; 303: 109-15.
9. Langer G, Walter S, Behrens-Baumann W, Hoffmann W. TFF peptides. New mucus-associated secretory products of the conjunctiva. Ophthalmologe 2001; 98: 976-9.
10. Paulsen FP, Hinz M, Schaudig U, Thale AB, Hoffmann W. TFF peptides in the human efferent tear ducts. Invest Ophthalmol Vis Sci 2002; 43: 3359-64.
11. Hoffmann W, Jagla W, Wiede A. Molecular medicine of TFF-peptides: from gut to brain. Histol Histopathol 2001; 16: 319-34.
12. Rio MC, Chambon P. The pS2 gene, mRNA, and protein: a potential marker for human breast cancer. Cancer Cells 1990; 2: 269-74.
13. Thim L. Trefoil peptides: a new family of gastrointestinal molecules. Digestion 1994; 55: 353-60.
14. Hoffmann W, Hauser F. The P-domain or trefoil motif: a role in renewal and pathology of mucous epithelia? Trends Biochem Sci 1993; 18: 239-43.
15. RibierasS, Tomasetto C, Rio MC. The pS2/TFF1 trefoil factor, from basic research to clinical applications. Biochim Biophys Acta 1998; 1378: F61-F77.
16. Thim L. Trefoil peptides: from structure to function. Cell Mol Life Sci 1997; 53: 888-903.
17. Newton JL, Allen A, Westley BR, May FE. The human trefoil peptide, TFF1, is present in different molecular forms that are intimately associated with mucus in normal stomach. Gut 2000; 46: 312-20.
18. May FE, Semple JI, Newton JL, Westley BR. The human two domain trefoil protein, TFF2, is glycosylated in vivo in the stomach. Gut 2000; 46: 454-9.
19. Muskett FW, May FE, Westley BR, Feeney J. Solution structure of the disulfide-linked dimer of human intestinal trefoil factor (TFF3): the intermolecular orientation and interactions are markedly different from those of other dimeric trefoil proteins. Biochemistry 2003; 42: 15139-47.
20. Williams MA, Westley BR, May FE, Feeney J. The solution structure of the disulphide-linked homodimer of the human trefoil protein TFF1. FEBS Lett 2001; 493: 70-4.
21. Ludeking A, Fegert P, Blin N, Gott P. Osmotic changes and ethanol modify TFF gene expression in gastrointestinal cell lines. FEBS Lett 1998; 439: 180-4.
22. Vestergaard EM, Brynskov J, Ejskjaer K, Clausen JT, Thim L, Nexo E, et al. Immunoassays of human trefoil factors 1 and 2: measured on serum from patients with inflammatory bowel disease. Scand J Clin Lab Invest 2004; 64: 146-56.
23. Chenard MP, Tomasetto C, Bellocq JP, Rio MC. Urinary pS2/TFF1 levels in the management of hormonodependent breast carcinomas. Peptides 2004; 25: 737-43.
24. Tomasetto C, Wolf C, Rio MC, Mehtali M, LeMeur M, Gerlinger P, et al. Breast cancer protein PS2 synthesis in mammary gland of transgenic mice and secretion into milk. Mol Endocrinol 1989; 3: 1579-84.
25. Lefebvre O, Chenard MP, Masson R, Linares J, Dierich A, LeMeur M, et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 1996; 274: 259-62.
26. Weinberg RA. Oncogenes and tumor suppressor genes. Trans Stud Coll Physicians Phila 1988; 10: 83-94.
27. Karam SM, Tomasetto C, Rio MC. Trefoil factor 1 is required for the commitment programme of mouse oxyntic epithelial progenitors. Gut 2004; 53: 1408-15.
28. Saukkonen K, Rintahaka J, Sivula A, Buskens CJ, Van Rees BP, Rio MC, et al. Cyclooxygenase-2 and gastric carcinogenesis. APMIS 2003; 111: 915-25.
29. Saukkonen K, Tomasetto C, Narko K, Rio MC, Ristimaki A. Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice. Cancer Res 2003; 63: 3032-6.
30. Tomasetto C, Masson R, Linares JL, Wendling C, Lefebvre O, Chenard MP, et al. pS2/TFF1 interacts directly with the VWFC cysteine-rich domains of mucins. Gastroenterology 2000; 118: 70-80.
31. Luqmani YA, Campbell T, Soomro S, Shousha S, Rio MC, Coombes RC. Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. Br J Cancer 1993; 67: 749-53.
32. Rye PD, Dookeran K, Walker RA. Expression of the pS2 peptide in normal human glandular endometrium during the menstrual cycle: a possible function. Dis Markers 1993; 11: 23-8.
33. Thim L, Madsen F, Poulsen SS. Effect of trefoil factors on the viscoelastic properties of mucus gels. Eur J Clin Invest 2002; 32: 519-27.
34. Playford RJ, Marchbank T, Goodlad RA, Chinery RA, Poulsom R, Hanby AM. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc Natl Acad Sci USA 1996; 93: 2137-42.
35. Clyne M, Dillon P, Daly S, O'Kennedy R, May FE, Westley BR, et al. Helicobacter pylori interacts with the human single-domain trefoil protein TFF1. Proc Natl Acad Sci USA 2004; 101: 7409-14.
36. Rio MC, Chenard MP, Wolf C, Marcellin L, Tomasetto C, Lathe R, et al. Induction of pS2 and hSP genes as markers of mucosal ulceration of the digestive tract. Gastroenterology 1991; 100: 375-9.
37. Shaoul R, Okada Y, Cutz E, Marcon MA. Colonic expression of MUC2, MUC5AC, and TFF1 in inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr 2004; 38: 488-93.
38. FitzGerald AJ, Pu M, Marchbank T, Westley BR, May FE, Boyle J, et al. Synergistic effects of systemic trefoil factor family 1 (TFF1) peptide and epidermal growth factor in a rat model of colitis. Peptides 2004; 25: 793-801.
39. Abadjian G, Antoun R. Breast carcinoma: evaluation of hormone receptors and pS2, erb-B2, P-glycoprotein and Ki-67 markers. J Med Liban 1996; 14: 10-5.
40. Spyratos F, Andrieu C, Hacene K, Chambon P, Rio MC. pS2 and response to adjuvant hormone therapy in primary breast cancer. Br J Cancer 1994; 69: 394-7.
41. Foekens JA, Rio MC, Seguin P, van Putten WL, Fauque J, Nap M, et al. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 1990; 50: 3832-7.
42. Balleine RL, Clarke CL. Expression of the oestrogen responsive protein pS2 in human breast cancer. Histol Histopathol 1999; 14: 571-8.
43. Ruibal A, Nunez MI, del Rio M, Arias J, Martinez MI, Rabadan J, et al. Clinical-biological differences between invasive ductal carcinomas and breast lobular carcinomas. Preliminary results. Rev Esp Med Nucl 1999; 18: 84-7.
44. Wu MS, Shun CT, Wang HP, Lee WJ, Wang TH, Lin JT. Loss of pS2 protein expression is an early event of intestinal-type gastric cancer. Jpn J Cancer Res 1998; 89: 278-82.
45. Park WS, Oh RR, Park JY, Lee JH, Shin MS, Kim HS, et al. Somatic mutations of the trefoil factor family 1 gene in gastric cancer. Gastroenterology 2000; 119: 691-8.
46. Fujimoto J, Yasui W, Tahara H, Tahara E, Kudo Y, Yokozaki H, et al. DNA hypermethylation at the pS2 promoter region is associated with early stage of stomach carcinogenesis. Cancer Lett 2000; 149: 125-34.
47. Katoh M. Trefoil factors and human gastric cancer. Int J Mol Med 2003; 12: 3-9.
48. Suarez C, Vizoso F, Rodriguez JC, Garcia I, Raigoso P, Allende MT, et al. Prognostic significance of cytosolic pS2 protein content in gastric cancer. Int J Biol Markers 2001; 16: 37-44.
49. Satge D, Sasco AJ, Geneix A, Malet P. Another reason to look for tumor suppressor genes on chromosome 21. Genes Chromosom Cancer 1998; 21: 1.
50. Sagol O, Tuna B, Coker A, Karademir S, Obuz F, Astarcioglu H, et al. Immunohistochemical detection of pS2 protein and heat shock protein-70 in pancreatic adenocarcinomas. Relationship with disease extent and patient survival. Pathol Res Pract 2002; 198: 77-84.
51. Sasaki M, Tsuneyama K, Nakanuma Y. Aberrant expression of trefoil factor family 1 in biliary epithelium in hepatolithiasis and cholangiocarcinoma. Lab Invest 2003; 83: 1403-13.
52. Welter C, Theisinger B, Rio MC, Seitz G, Schuder G, Blin N. Expression pattern of breast-cancer-associated protein pS2/BCEI in colorectal tumors. Int J Cancer 1991; 56: 52-5.
53. Vizoso FJ, Fagilde MC, Corte MD, Corte MG, Gava R, Bongera M, et al. Cytosolic levels of an estrogen-induced breast cancer-associated peptide (TFF1/pS2) in colorectal cancer: clinical significance and relationship with steroid receptors. Int J Biol Markers 2003; 18: 301-10.
54. Bonkhoff H, Stein U, Welter C, Remberger K. Differential expression of the pS2 protein in the human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation. Hum Pathol 1995; 26: 821-8.
55. Yang Y, Chisholm GD, Habib FK. The distribution of PSA, cathepsin-D, and pS2 in BPH and cancer of the prostate. Prostate 1992; 21: 201-8.
56. Colombel M, Dante R, Bouvier R, Ribieras S, Pangaud C, Marechal JM, et al. Differential RNA expression of the pS2 gene in the human benign and malignant prostatic tissue. Prostate Cancer Prostatic Dis 1999; 2: S11.
57. Wang DG, Liu WH, Lundy FT, Pogue KM, Cunningham RT, Johnston CF, et al. TFF1 gene expression in human medullary thyroid carcinoma. J Pathol 1998; 184: 408-13.
58. Ruibal A, Nunez MI, del Rio MC, Garcia Diez S, Rodriguez J, Alvarez De Linera JA. Cytosolic pS2 levels in 154 non-small-cell lung carcinomas. Correlation with other clinical and biological parameters. Rev Esp Med Nucl 2002; 21: 109-14.
59. Bossenmeyer-Pourie C, Kannan R, Ribieras S, Wendling C, Stoll I, Thim L, et al. The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J Cell Biol 2002; 157: 761-70.
60. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1: 222-31.
61. Zheng L, Lee WH. The retinoblastoma gene: a prototypic and multi-functional tumor suppressor. Exp Cell Res 2001; 264: 2-18.
62. Nunez G, Benedict MA, Hu Y, Inohara N. Caspases: the proteases of the apoptotic pathway. Oncogene 1998; 17: 3237-45.
63. Datta R, Oki E, Endo K, Biedermann V, Ren J, Kufe D. XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage. J Biol Chem 2000; 275: 31733-8.
64. Tebbutt NC, Giraud AS, Inglese M, Jenkins B, Waring P, Clay FJ, et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 2002; 8: 1089-97.
65. Wright NA, Poulsom R, Stamp G, Van Noorden S, Sarraf C, Elia G, et al. Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology 1993; 104: 12-20.
66. Wright NA, Poulsom R, Stamp G, Van Norden S, Sarraf C, Elia G, et al. Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Scand J Gastroenterol 1992; 193: 76-82.
67. Emami S, Rodrigues S, Rodrigue CM, Le Floch N, Rivat C, Attoub S, et al. Trefoil factor family (TFF) peptides and cancer progression. Peptides 2004; 25: 885-98.
68. Rodrigues S, Nguyen QD, Faivre S, Bruyneel E, Thim L, Westley B, et al. Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways. FASEB J 2001; 15: 1517-28.
69. Rivat C, Rodrigues S, Bruyneel E, Pietu G, Robert A, Redeuilh G, et al. Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3) - and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res 2005; 65: 195-202.
70. Rodrigues S, Van Aken E, Van Bocxlaer S, Attoub S, Nguyen QD, Bruyneel E, et al. Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. FASEB J 2003; 17: 7-16.